Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 130

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 130
---
 may be terminated by either party for cause. Radiopharm has the right
to terminate the agreement at will upon providing a 90-day notice.

Sublicense Agreement with NeoIndicate

In June 2022, Radiopharm entered
into a sublicense agreement with NeoIndicate LLC (“ NeoIndicate”) pursuant to which NeoIndicate granted an exclusive, worldwide
sublicensable sublicense to Radiopharm for certain parent rights concerning imaging and theranostics uses of molecular agents targeting
cell surface receptor PTPmu developed by Case Western Reserve University (“ CWRU”). Radiopharm has paid US$70,000 in upfront
fees. In addition, under the terms of the agreement, Radiopharm will pay NeoIndicate an annual license maintenance fee in an amount that
is less than the upfront fee and up to US$278.3 million upon achievement of the certain development milestones and single-digit royalty
rates on net annual sales of licensed products in the relevant fiscal year. For further details, please see Note 13(e) to our fiscal 2025
audited financial statements in this Annual Report.

The term of the agreement
shall conclude on the later of the end of 20 years from the effective date of the license agreement between CWRU and NeoIndicate, or on
the expiration date of the last-to-expire patent covered by the agreement, or on the expiration date of the last-to-expire market exclusivity
period. The expected expiry date of the last-to-expire patent 2037. Radiopharm may terminate the agreement by giving 60 days written notice
to NeoIndicate. NeoIndicate retained the right to terminate the agreement if certain milestone developments are not achieved within the
deadlines specified in the agreement.

Stock Purchase Agreement with Pharma15 and its selling stockholders

In March 2023, Radiopharm
and Radiopharm Theranostics (USA) Inc. entered into a Stock Purchase Agreement with Pharma 15 and its stockholders. Under the terms of
the agreement, our wholly-owned subsidiary Radiopharm Theranostics (USA) Inc. acquired 100% of Pharma15’s outstanding shares of
common stock. As consideration, we agreed to pay US$4 million, as adjusted for any assets or liabilities held by Pharma15 and transaction
expenses. In particular, we agreed to pay (i) at closing, US$1 million in cash and an amount of Radiopharm ordinary shares equivalent
to US